Ziopharm rebrands to Alaunos, closes Boston office with new CEO at the reins
A little over a year after facing an activist attack that saw former CEO Laurence Cooper survive but retire a few months later, Ziopharm Oncology will undergo a rebranding and restructuring.
Its new company name will be Alaunos Therapeutics, the biotech announced Thursday, aiming to put its checkered past behind it. In addition, Alaunos has closed its Boston office and will move its headquarters to Houston — it’s unclear whether this will result in substantial layoffs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.